Welcome to our dedicated page for Glaukos news (Ticker: GKOS), a resource for investors and traders seeking the latest updates and insights on Glaukos stock.
Glaukos Corporation develops and commercializes ophthalmic pharmaceutical and medical technology products for glaucoma, corneal disorders, and retinal diseases. News about Glaukos regularly covers financial results, global commercial execution, and updates for its dropless platform technologies, including iDose TR for sustained intracameral glaucoma drug delivery and Epioxa for corneal cross-linking in keratoconus.
Recurring company developments include FDA labeling actions for iDose TR, CMS coding and commercial availability updates for Epioxa, scientific presentations in ophthalmology, and quarterly sales trends across its glaucoma franchise. Company background also includes Micro-Invasive Glaucoma Surgery products such as iStent, iStent inject W, and iStent infinite, along with a pipeline aimed at chronic eye diseases.
Glaukos Corporation (NYSE: GKOS) announced management's participation in the Stephens Annual Investment Conference on November 16, 2022, at 2:00 p.m. CT in Nashville, TN. The event will be accessible via a live and archived webcast on their Investors section of the website. Glaukos specializes in ophthalmic medical technology and pharmaceuticals, focusing on innovative treatments for glaucoma, corneal disorders, and retinal diseases. They pioneered Micro-Invasive Glaucoma Surgery (MIGS) to enhance glaucoma treatment.
Glaukos Corporation (GKOS) reported third-quarter 2022 net sales of $71.3 million, a decline of 4.6% year-over-year. The glaucoma segment generated $53.7 million, while corneal health contributed $17.5 million. Gross margin was approximately 76%, down from 79% in Q3 2021. SG&A expenses rose 6% to $47.1 million, and R&D expenses slightly increased. The net loss was $27.6 million or ($0.58) per diluted share. The company updated its 2022 net sales guidance to $278 million to $280 million. Glaukos ended the quarter with approximately $371 million in cash and equivalents.
Glaukos Corporation (NYSE: GKOS) announces its third quarter 2022 financial results will be released after market close on November 2, 2022. A conference call and webcast will follow at 1:30 p.m. PT (4:30 p.m. ET) for management to discuss the results. The company focuses on novel therapies for glaucoma, corneal disorders, and retinal diseases, having pioneered Micro-Invasive Glaucoma Surgery (MIGS) since 2012. A replay of the call will be available on Glaukos' website post-event.
Glaukos Corporation (NYSE: GKOS) announces its participation in the American Academy of Ophthalmology (AAO) annual meeting, September 30 - October 3, 2022, in Chicago, IL. The company will showcase advancements in glaucoma and corneal health technologies. Key topics include novel intraoperative OCT use, trabecular bypass surgery efficacy, and corneal health presentations. Glaukos will exhibit at booth #4503, highlighting their commitment to innovative ophthalmic treatments. Further details and abstracts are available on the AAO website.
Glaukos Corporation (NYSE: GKOS) announced that both iDose TR Phase 3 pivotal trials achieved their primary efficacy endpoints. The trials showed that 93% of slow-release iDose TR subjects remained well-controlled on the same or fewer IOP-lowering medications at 12 months, with 81% completely medication-free. The treatment demonstrated excellent tolerability, with 98% continuing after 12 months, and a favorable safety profile. Glaukos is preparing for an NDA submission to the FDA, with a decision expected by the end of 2023.
Glaukos Corporation (NYSE: GKOS) has announced a major milestone with over one million implantations of its iStent technology worldwide. This achievement underscores Glaukos' pioneering role in Micro-Invasive Glaucoma Surgery (MIGS), reflecting more than 20 years of innovation and investment in glaucoma treatment options.
Industry experts emphasize that iStent has significantly improved patient outcomes and allowed for earlier interventions in glaucoma treatment. Glaukos continues to invest over 30% of its revenue into research and development to enhance its product offerings.
On August 24, iVeena Delivery Systems entered a strategic licensing agreement with Glaukos Corporation (GKOS) for IVMED-80, an eye drop designated for keratoconus. Glaukos paid $10 million upfront and will cover all development costs. The deal includes potential milestone payments and royalties for iVeena. iVeena is also working on IVMED-85, aimed at pediatric myopia, with plans for a clinical trial in early 2023.
Glaukos Corporation (NYSE: GKOS), a leader in ophthalmic medical technology, has announced its management will participate in the Wells Fargo Healthcare Conference on September 7, 2022, at 3:45 p.m. ET in Boston, MA. This event will highlight Glaukos' focus on novel therapies for treating glaucoma, corneal disorders, and retinal diseases. A live webcast will be available in the Investors section of the Glaukos website.
iVeena Delivery Systems has entered a strategic licensing agreement with Glaukos Corporation (NYSE: GKOS) for exclusive global rights to IVMED-80, a treatment for keratoconus, a rare corneal disorder. IVMED-80 is a proprietary topical eye drop that has shown promising results in a phase 1/2a clinical study, achieving a significant reduction in corneal curvature. Glaukos paid $10 million upfront for the license and will cover all development costs, with further milestone payments and royalties possible. This partnership aims to enhance treatment options for keratoconus patients.
Glaukos Corporation (NYSE: GKOS) has received 510(k) clearance from the U.S. FDA for its iStent infinite Trabecular Micro-Bypass System, the first micro-invasive implantable device approved for standalone glaucoma treatment. This innovative device features a three-stent system designed to lower intraocular pressure (IOP) by restoring natural fluid outflow. CEO Thomas Burns highlighted the device's potential, backed by compelling clinical data. Initial commercial launch activities for iStent infinite are planned for later this year.